Metoprolol Aurovitas (Metoprolol Tartrate)

Metoprolol Tartrate selectively blocks β1‑adrenergic receptors in the heart, reducing the effects of sympathetic stimulation. This leads to a slower heart rate, decreased contractile force, and lower cardiac output, which together help to lower systemic blood pressure and lessen the heart's oxygen requirements.

The appropriate dose of Metoprolol Aurovitas is determined by a qualified healthcare professional based on the individual’s medical condition, response to therapy, and any concomitant medications. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety data for Metoprolol Aurovitas in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their healthcare provider.

To place an order, submit an enquiry on the Metoprolol Aurovitas product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Metoprolol is a cardio‑selective (β1‑selective) beta‑blocker, offering a favorable profile for patients with respiratory conditions compared with non‑selective agents like propranolol. Its relatively short half‑life allows flexible dosing, while agents such as atenolol have longer half‑lives. Choice of agent depends on individual patient characteristics, comorbidities, and physician preference.

Metoprolol Aurovitas tablets should be stored at ambient temperature, preferably below 25 °C, in the original container to protect from moisture and light. Keep the product out of reach of children and avoid storing in areas with high humidity or direct sunlight.

Metoprolol Aurovitas is taken orally, usually as a whole tablet swallowed with a glass of water. It can be taken with or without food, but consistency with respect to meals is recommended to maintain stable plasma levels. Patients should follow the dosing schedule prescribed by their clinician.

Serious adverse events include marked bradycardia, symptomatic hypotension, atrioventricular block, bronchospasm in susceptible individuals, and severe depression. Patients should seek immediate medical attention if they experience fainting, severe shortness of breath, chest pain, or any signs of an allergic reaction such as swelling or difficulty breathing.

Metoprolol Aurovitas is contraindicated in patients with severe bradycardia (heart rate < 45 bpm), second‑ or third‑degree AV block without a pacemaker, cardiogenic shock, decompensated heart failure, and uncontrolled asthma or severe chronic obstructive pulmonary disease. It should also be avoided in individuals with known hypersensitivity to metoprolol or any excipients.